NCT06004336
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Recruiting · Phase 2 · M.D. Anderson Cancer Center · registry updated 2026-07-16
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Inclusion
- In order to be eligible for trial participation, patients must have:
- The participant provides written informed consent for the trial.
- Pathologically confirmed diagnosis of RCC with a clear cell component.
- Be willing and able to undergo biopsy of a lesion planned for definitive RT. If a lesion amenable to SBRT was biopsied prior to enrollment, this material can be used in lieu of a planned biopsy if the tissue is available for review at MD Anderson.
- Patients may be allowed on this trial without a biopsy if they are deemed medically unfit for biopsy or if the biopsy poses undue risk in the opinion of the treating physician(s).
- Be ≥18 years of age on the day of signing informed consent.
Exclusion
- The patient must be excluded from participating in the trial based on the following conditions:
- \. The patient must have received their last dose of systemic therapy ≥24 weeks prior to initiation of their first dose of RT if this therapy included immunotherapy (e.g. pembrolizumab, nivolumab, ipilimumab, etc.) or ≥4 weeks prior to initiation of the first dose of radiation if this systemic therapy did not include immunotherapy.
- \. Immunocompromising conditions, as follows:
- Known acute or chronic human immunodeficiency virus (HIV) infection
- History of primary immunodeficiency
- History of allogeneic tissue/solid organ transplant